ERBB2 and neoplasm: Another explanation is that the more HER2 receptors are present in the membrane of tumor cells, the more molecules of trastuzumab (or other anti‐HER2 antibodies) can bind and prime antibody‐dependent cell cytotoxicity (ADCC).